Navigation Links
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:10/14/2010

ow and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of Oct. 14, 2010 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
2. Array BioPharma and Amgen Partner in Type 2 Diabetes
3. Amgen to Present at Lazard Capital Healthcare Conference
4. Amgen Announces Webcast of 2009 Third Quarter Financial Results
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
8. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
9. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
10. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
11. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... a leader in data visualization, today unveils a new ... hospital costs across the United States . The tool ... “Medicare Provider Charge Data,” a dataset of pricing information ... for Medicare & Medicaid Services. , The wide variation ... country has sparked considerable controversy; however, it is nearly ...
(Date:5/19/2013)... New York, NY (PRWEB) May 19, 2013 ... largest solar boat, today announced a new speed record ... Having left from Las Palmas, Spain, on April 25, ... across the Atlantic Ocean at the average speed of ... French West Indies on May 18, 2013. The first-of-its-kind ...
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
(Date:5/17/2013)... This news release is available in German . ... all too well: with the naked eye, you can see ... bird in the blur of branches through the telephoto lens ... story for researchers who are looking to study proteins, the ... at ETH Zurich,s Institute for Molecular Systems Biology, and her ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3
... Milestone triggers $10 million payment from Eli Lilly ... - BioMS Medical Corp. (TSX:,MS), a leading developer ... that the independent Drug Safety Monitoring Board (DSMB) ... analysis of efficacy,and safety and has recommended that ...
... Scotland, S.D. to start in Q4 ,08. , ... ... Coalition for Ethanol conference, http://www.poet.com [POET] announced that construction ... facility later this year. The pilot plant will be adjacent to ...
... ATSI ), manufacturer and marketer of state-of-the-art ... at the Fourth,Annual Noble Financial Equity Conference at ... Financial Officer of ATS Medical, will,present at 2:30 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), Attendance at ...
Cached Biology Technology:BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 3ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference 2
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... Biology (SDB) 72nd Annual Meeting in Cancun, Mexico ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... BOSTON The endothelium, the cellular layer lining ... just a few hundred nanometers in thickness, this ... stretch and tissue compression to create a unique ... necessary to partition tissues from the body,s circulatory ... when the barrier must be physically breached ...
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... Testing people for heart disease might be just a ... created by a team of researchers from Harvard and Northeastern ... The FASEB Journal ( http://www.fasebj.org ), they describe ... cells needed to build vascular tissue, called endothelial progenitor cells, ...
... Boston, MA June 1, 2009 REGiMMUNE Corporation ... combination with a low-dose of Sirolimus, demonstrated enhanced efficacy ... and acute Graft-versus-Host disease (GvHD). This data is ... Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone ...
... years modeled how different species are likely to respond ... populations within a species and the interactions between species, ... June issue of BioScience , by Eric Post ... these limitations can be avoided. Their approach, which relies ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2